Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAM HF-1
2012-001818-42Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Nov 2015
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rexlemestrocel-l in chronic heart failure (CHF) and left ventricular systolic dysfunction (LVSD) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Time-to recurrent non-fatal decompensated heart failure events in the presence of terminal HF-MACE. Started Nov 2015; status: terminated.
02
Drugs
rexlemestrocel-l
03
Conditions
chronic heart failure (CHF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on 2012-001818-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001818-42.